Hydrolytic Enzymes

Metabolism of Drugs and Other Xenobiotics

Volumn , Issue , 2012, Pages 165-198

  Yan, Bingfang ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Carboxylesterase; Catalysis; Classification nomenclature; Epoxide hydrolase; Hydrolytic enzyme; Paraoxonase; Structure

Indexed keywords

EID: 84872686993     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630905.ch6     Document Type: Chapter

References (125)

1. Sanghani, S.P., Sanghani, P.C., Schiel, M.A., and Bosron, W.F. (2009) Human carboxylesterases:an update on CES1, CES2 and CES3. Protein Pept. Lett., 16, 1207-1214.
2. Satoh, T. and Hosokawa, M. (2006) Structure, function and regulation of carboxylesterases. Chem. Biol. Interact., 162, 195-211.
3. Imai, T. (2006) Human carboxylesterase isozymes:catalytic properties and rational drug design. Drug Metab. Pharmacokinet., 21, 173-185.
4. Tang, M., Mukundan, M., Yang, J., Charpentier, N., LeCluyse, E.L., Black, C., Yang, D., Shi, D., and Yan, B. (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther., 319, 1467-1476.
5. Bora, P.S., Guruge, B.L., and Bora, N.S. (2003) Molecular characterization of human eye and heart fatty acid ethyl ester synthase/carboxylesterase by site-directed mutagenesis. Biochem. Biophys. Res. Commun., 312, 1094-1098.
6. Zhao, B., Natarajan, R., and Ghosh, S. (2005) Human liver cholesteryl ester hydrolase:cloning, molecular characterization, and role in cellular cholesterol homeostasis. Physiol. Genomics, 23, 304-310.
7. Wei, E., Alam, M., Sun, F., Agellon, L.B., Vance, D.E., and Lehner, R. (2007) Apolipoprotein B and triacylglycerol secretion in human triacylglycerol hydrolase transgenic mice. J. Lipid Res., 48, 2597-2606.
8. Yang, D., Wang, X., Yang, D., and Yan, B. (2009) Pyrethroid insecticides:isoform-dependent hydrolysis, induction of cytochrome P450 3A4 and evidence on the involvement of the pregnane X receptor. Toxicol. Appl. Pharmacol., 237, 49-58.
9. Maxwell, D.M., Lieske, C.N., and Brecht, K.M. (1994) Oxime-induced reactivation of carboxylesterase inhibited by organophosphorus compounds. Chem. Res. Toxicol., 7, 428-433.
10. Zhu, B.T., Evaristus, E.N., Antoniak, S.K., Sarabia, S.F., Ricci, M.J., and Liehr, J.G. (1996) Metabolic deglucuronidation and demethylation of estrogen conjugates as a source of parent estrogens and catecholestrogen metabolites in Syrian hamster kidney, a target organ of estrogen-induced tumorigenesis. Toxicol. Appl. Pharmacol., 136, 186-193.
11. Junge, W. and Krisch, K. (1973) Current problems on the structure and classification of mammalian liver carboxylesterases (EC 3.1.1.1). Mol. Cell. Biochem., 1, 41-52.
12. Holmes, R.S., Cox, L.A., and Vandeberg, J.L. (2008) Mammalian carboxylesterase 5:comparative biochemistry and genomics. Comp. Biochem. Physiol. D, 3, 195-204.
13. Holmes, R.S., Cox, L.A., and Vandeberg, J.L. (2009) A new class of mammalian carboxylesterase CES6. Comp. Biochem. Physiol. D, 4, 209-217.
14. Hosokawa, M., Furihata, T., Yaginuma, Y., Yamamoto, N., Watanabe, N., Tsukada, E., Ohhata, Y., Kobayashi, K., Satoh, T., and Chiba, K. (2008) Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metab. Pharmacokinet., 23, 73-84.
15. Yan, B., Matoney, L., and Yang, D. (1999) Human placental carboxylesterases:enzymatic characterization, molecular cloning, and evidence for the existence of multiple forms. Placenta, 20, 599-607.
16. Kroetz, D.L., McBride, O.W., and Gonzalez, F.J. (1993) Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases:cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry, 32, 11606-11617.
17. Wu, M.H., Chen, P., Remo, B.F., Cook, E.H., Jr, Das, S., and Dolan, M.E. (2003) Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics, 13, 425-435.
18. Sanghani, S.P., Quinney, S.K., Fredenburg, T.B., Davis, W.I., Murry, D.J., and Bosron, W.F. (2004) Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab. Dispos., 32, 505-511.
19. Yan, B., Yang, D., Brady, M., and Parkinson, A. (1994) Rat kidney carboxylesterase:cloning, sequencing, cellular localization and relationship to liver hydrolase B. J. Biol. Chem., 269, 29688-29696.
20. Yan, B., Yang, D., Brady, M., and Parkinson, A. (1995) Rat testicular carboxylesterase:cloning, sequencing, cellular localization and relationship to liver hydrolase A. Arch. Biochem. Biophys., 316, 899-908.
21. Yan, B., Yang, D., Bolluck, P., and Parkinson, A. (1996) Rat serum carboxylesterase:cloning, expression, regulation and evidence of secretion from liver. J. Biol. Chem., 270, 19128-19134.
22. Song, X., Gragen, S., Li, Y., Ma, Y., Liu, J., Yang, D., Matoney, L., and Yan, B. (2004) Intramolecular disulfide bonds are required for folding hydrolase B into a catalytically active conformation but not for maintaining it during catalysis. Biochem. Biophys. Res. Commun., 319, 1072-1080.
23. Ollis, D.L., Cheah, E., Cygler, M., Dijkstra, B., Frolow, F., Franken, S.M., Harel, M., Remington, S.J., Silman, I., Schrag, J., Sussman, J.L., Verschueren, K.H.G., and Goldman, A. (1992) The α/β hydrolase fold. Protein Eng., 5, 197-211.
24. Bencharit, S., Morton, C.L., Xue, Y., Potter, P.M., and Redinbo, M.R. (2003) Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol., 10, 349-356.
25. Sussman, J.L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., and Silman, I. (1991) Atomic structure of acetylcholinesterase from Torpedo californica:a prototypic acetylcholine-binding protein. Science, 253, 872-879.
26. Bencharit, S., Morton, C.L., Howard-Williams, E.L., Danks, M.K., Potter, P.M., and Redinbo, M.R. (2002) Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat. Struct. Biol., 9, 337-342.
27. Shi, D., Yang, J., Yang, D., LeCluyse, E.L., Black, C., You, L., Akhlaghi, F., and Yan, B. (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase HCE1 and the activation is inhibited by anti-platelet agent clopidogrel. J. Pharmacol. Exp. Ther., 319, 1477-1484.
28. Luttrell, W.E. and Castle, M.C. (1993) Enhancement of hepatic microsomal esterase activity following soman pretreatment in guinea pigs. Biochem. Pharmacol., 46, 2083-2092.
29. Wheelock, C.E., Nishi, K., Ying, A., Jones, P.D., Colvin, M.E., Olmstead, M.M., and Hammock, B.D. (2008) Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH). Bioorg. Med. Chem., 16, 2114-2130.
30. Hicks, L.D., Hyatt, J.L., Stoddard, S., Tsurkan, L., Edwards, C.C., Wadkins, R.M., and Potter, P.M. (2009) Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan; CPT-11) toxicity. J. Med. Chem., 52, 3742-3752.
31. Harada, T., Nakagawa, Y., Wadkins, R.M., Potter, P.M., and Wheelock, C.E. (2009) Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis. Bioorg. Med. Chem., 17, 149-164.
32. Taylor, P. and Radic, Z. (1994) The cholinesterases:from genes to proteins. Annu. Rev. Pharmacol. Toxicol., 34, 281-320.
33. Alvares, A.P. and Pratt, W.B. (1990) Pathways of drug metabolism, in Principle of Drug Action, 2nd edn (eds W.B. Pratt and P. Taylor), Churchill Livingstone, London, pp. 383-384.
34. Perucca, E., Cloyd, J., Critchley, D., and Fuseau, E. (2008) Rufinamide:clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia, 49, 1123-1141.
35. Pindel, E.V., Kedishvili, N.Y., Abraham, T.L., Brzezinski, M.R., Zhang, J., Dean, R.A., and Bosron, W.F. (1997) Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem., 272, 14769-14775.
36. Schentag, J.J., Hill, G., Chu, T., and Rayner, C.R. (2007) Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J. Clin. Pharmacol., 47, 689-696.
37. Abe, M., Smith, J., Urae, A., Barrett, J., Kinoshita, H., and Rayner, C.R. (2006) Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother., 40, 1724-1730.
38. Morgan, E.W., Yan, B., Petersen, D., Greenway, D., and Parkinson, A. (1994) Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B). Arch. Biochem. Biophys., 315, 494-513.
39. Hosokawa, M., Endo, T., Fujisawa, M., Hara, S., Iwata, N., Sato, Y., and Satoh, T. (1995) Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab. Dispos., 23, 1022-1027.
40. Wadkins, R.M., Hyatt, J.L., Edwards, C.C., Tsurkan, L., Redinbo, M.R., Wheelock, C.E., Jones, P.D., Hammock, B.D., and Potter, P.M. (2007) Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds. Mol. Pharmacol., 71, 713-723.
41. Nemoda, Z., Angyal, N., Tarnok, Z., Gadoros, J., and Sasvari-Szekely, M. (2009) Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology, 57, 731-733.
42. Ribelles, N., López-Siles, J., Sánchez, A., González, E., Sánchez, M.J., Carabantes, F., Sánchez-Rovira, P., Márquez, A., Dueñas, R., Sevilla, I., and Alba, E. (2008) A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr. Drug Metab., 9, 336-343.
43. Kim, S.R., Sai, K., Tanaka-Kagawa, T., Jinno, H., Ozawa, S., Kaniwa, N., Saito, Y., Akasawa, A., Matsumoto, K., Saito, H., Kamatani, N., Shirao, K., Yamamoto, N., Yoshida, T., Minami, H., Ohtsu, A., Saijo, N., and Sawada, J. (2007) Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab. Dispos., 35, 1865-1872.
44. Bellott, R., Le Morvan, V., Charasson, V., Laurand, A., Colotte, M., Zanger, U.M., Klein, K., Smith, D., Bonnet, J., and Robert, J. (2008) Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother. Pharmacol., 61, 481-488.
45. Geshi, E., Kimura, T., Yoshimura, M., Suzuki, H., Koba, S., Sakai, T., Saito, T., Koga, A., Muramatsu, M., and Katagiri, T. (2005) A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens. Res., 28, 719-725.
46. Kubo, T., Kim, S.R., Sai, K., Saito, Y., Nakajima, T., Matsumoto, K., Saito, H., Shirao, K., Yamamoto, N., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Ohno, Y., Ozawa, S., and Sawada, J. (2005) Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab. Dispos., 33, 1482-1487.
47. Guillemette, C. (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J., 3, 136-158.
48. Muntané, J. (2009) Regulation of drug metabolism and transporters. Curr. Drug Metab., 10, 932-945.
49. Russel, F.G., Koenderink, J.B., and Masereeuw, R. (2008) Multidrug resistance protein 4 (MRP4/ABCC4):a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci., 29, 200-207.
50. Zhu, H.J., Patrick, K.S., Yuan, H.J., Wang, J.S., Donovan, J.L., DeVane, C.L., Malcolm, R., Johnson, J.A., Youngblood, G.L., Sweet, D.H., Langaee, T.Y., and Markowitz, J.S. (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man:clinical significance and molecular basis. Am.J. Hum. Genet., 82, 1241-1248.
51. Shi, D., Yang, J., Yang, D., You, L., and Yan, B. (2008) Dexamethasone suppresses the expression of multiple rat carboxylesterases through transcriptional repression:evidence for an involvement of the glucocorticoid receptor. Toxicology, 254, 97-105.
52. Williams, E.T., Jones, K.O., Ponsler, G.D., Lowery, S.M., Perkins, E.J., Wrighton, S.A., Ruterbories, K.J., Kazui, M., and Farid, N.A. (2008) The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab. Dispos., 36, 1227-1232.
53. Farid, N.A., Payne, C.D., Small, D.S., Winters, K.J., Ernest, C.S., 2nd, Brandt, J.T., Darstein, C., Jakubowski, J.A., and Salazar, D.E. (2007) Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther., 81, 735-741.
54. Clarke, T.A. and Waskell, L.A. (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos., 31, 53-59.
55. Lau, W.C., Gurbel, P.A., Watkins, P.B., Neer, C.J., Hopp, A.S., Carville, D.G., Guyer, K.E., Tait, A.R., and Bates, E.R. (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 109, 166-171.
56. Charasson, V., Haaz, M.C., and Robert, J. (2002) Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab. Dispos., 30, 731-733.
57. Schulz, C., Boeck, S., Heinemann, V., and Stemmler, H.J. (2009) UGT1A1 genotyping:a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs, 20, 867-879.
58. Ramchandani, R.P., Wang, Y., Booth, B.P., Ibrahim, A., Johnson, J.R., Rahman, A., Mehta, M., Innocenti, F., Ratain, M.J., and Gobburu, J.V. (2007) The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J. Clin. Pharmacol., 47, 78-86.
59. Ose, A., Ito, M., Kusuhara, H., Yamatsugu, K., Kanai, M., Shibasaki, M., Hosokawa, M., Schuetz, J.D., and Sugiyama, Y. (2009) Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carbox ylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab. Dispos., 37, 315-321.
60. Ose, A., Kusuhara, H., Yamatsugu, K., Kanai, M., Shibasaki, M., Fujita, T., Yamamoto, A., and Sugiyama, Y. (2008) P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab. Dispos., 36, 427-434.
61. Ogihara, T., Kano, T., Wagatsuma, T., Wada, S., Yabuuchi, H., Enomoto, S., Morimoto, K., Shirasaka, Y., Kobayashi, S., and Tamai, I. (2009) Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab. Dispos., 37, 1676-1681.
62. Tian, Q., Zhang, J., Tan, T.M., Chan, E., Duan, W., Chan, S.Y., Boelsterli, U.A., Ho, P.C., Yang, H., Bian, J.S., Huang, M., Zhu, Y.Z., Xiong, W., Li, X., and Zhou, S. (2005) Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res., 22, 1837-1853.
63. Dettbarn, W.D., Yang, Z.P., and Milatovic, D. (1999) Different role of carboxylesterases in toxicity and tolerance to paraoxon and DFP. Chem. Biol. Interact., 119-120, 445-454.
64. Zhu, W., Song, L., Matoney, L., LeCluyse, E., and Yan, B. (2000) Dexamethasone differentially regulates the expression of carboxylesterase genes in humans and rats. Drug Metab. Dispos., 28, 186-191.
65. Jewell, C., Ackermann, C., Payne, N.A., Fate, G., Voorman, R., and Williams, F.M. (2007) Specificity of procaine and ester hydrolysis by human, minipig, and rat skin and liver. Drug Metab. Dispos., 35, 2015-2022.
66. Cecchin, E., Corona, G., Masier, S., Biason, P., Cattarossi, G., Frustaci, S., Buonadonna, A., Colussi, A., and Toffoli, G. (2005) Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin. Cancer Res., 11, 6901-6907.
67. Na, K., Lee, E.Y., Lee, H.J., Kim, K.Y., Lee, H., Jeong, S.K., Jeong, A.S., Cho, S.Y., Kim, S.A., Song, S.Y., Kim, K.S., Cho, S.W., Kim, H., and Paik, Y.K. (2009) Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics, 9, 3989-3999.
68. Fowler, S., Lennon, S.M., Hoffmann, G., and Rayner, C.R. (2007) Comments on "Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel". J. Pharmacol. Exp. Ther., 322, 422-423.
69. Morgan, E.W., Yan, B., Greenway, D., and Parkinson, A. (1994) Regulation of two rat liver microsomal carboxylesterase isozymes:species differences, tissue distribution and the effects of age, sex and xenobiotic treatment of rats. Arch. Biochem. Biophys., 315, 514-526.
70. Godin, S.J., Scollon, E.J., Hughes, M.F., Potter, P.M., DeVito, M.J., and Ross, M.K. (2006) Species differences in the in vitro metabolism of deltamethrin and esfenvalerate:differential oxidative and hydrolytic metabolism by humans and rats. DrugMetab. Dispos., 34, 1764-1771.
71. Luttrell, W.E. and Castle, M.C. (1988) Species differences in the hydrolysis of meperidine and its inhibition by organophosphate compounds. Fundam. Appl. Toxicol., 11, 323-332.
72. Liu, K., Guengerich, F.P., and Yang, S.K. (1991) Enantioselective hydrolysis of lorazepam 3-acetate by esterases in human and rat liver microsomes and rat brain S9 fraction. Drug Metab. Dispos., 19, 609-613.
73. Yang, D., Pearce, R., Wang, X., Gaedigk, R., Wan, Y.J.Y., and Yan, B. (2009) Human carboxylesterases HCE1 and HCE2:ontogenic expression, interindividual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol., 77, 238-247.
74. Yang, D., Li, Y., Yuan, X., Matoney, L., and Yan, B. (2001) Regulation of rat carboxylesterase expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) involves multiple signaling pathways. Toxicol. Sci., 64, 20-27.
75. Yang, J., Shi, D., Yang, D., Song, X., and Yan, B. (2007) Interleukin-6 suppresses the expression of carboxylesterases HCE1 and HCE2 through transcriptional repression. Mol. Pharmacol., 72, 686-694.
76. Zhu, H.J., Appel, D.I., Jiang, Y., and Markowitz, J.S. (2009) Age-and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab. Dispos., 37, 1819-1825.
77. Lake, B.G., Renwick, A.B., Cunninghame, M.E., Price, R.J., Surry, D., and Evans, D.C. (1998) Comparison of the effects of some CYP3A and other enzyme inducers on replicative DNA synthesis and cytochrome P450 isoforms in rat liver. Toxicology, 131, 9-20.
78. Barth, S., Fischer, M., Schmid, R.D., and Pleiss, J. (2004) Sequence and structure of epoxide hydrolases:a systematic analysis. Proteins, 55, 846-855.
79. Oguro, A., Sakamoto, K., Suzuki, S., and Imaoka, S. (2009) Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth. Biol. Pharm. Bull., 32, 1962-1967.
80. Marino, J.P., Jr (2009) Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr. Top. Med. Chem., 9, 452-463.
81. Morisseau, C. and Hammock, B.D. (2005) Epoxide hydrolases:mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol., 45, 311-333.
82. Wickliffe, J.K., Herring, S.M., Hallberg, L.M., Galbert, L.A., Masters, O.E., 3rd, Ammenheuser, M.M., Xie, J., Friedberg, E.C., Lloyd, R.S., Abdel-Rahman, S.Z., and Ward, J.B., Jr (2007) Detoxification of olefinic epoxides and nucleotide excision repair of epoxide-mediated DNA damage:insights from animal models examining human sensitivity to 1, 3-butadiene. Chem. Biol. Interact., 166, 226-231.
83. Azzato, E.M., Chen, R.A., Wacholder, S., Chanock, S.J., Klebanoff, M.A., and Caporaso, N.E. (2010) Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations. Pharmacogenet. Genomics, 20, 58-63.
84. Zheng, J., Plopper, C.G., Lakritz, J., Storms, D.H., and Hammock, B.D. (2001) Leukotoxin-diol:a putative toxic mediator involved in acute respiratory distress syndrome. Am. J. Respir. Cell Mol. Biol., 25, 434-438.
85. Imig, J.D. and Hammock, B.D. (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov., 8, 794-805.
86. Imig, J.D. (2010) Targeting epoxides for organ damage in hypertension. J. Cardiovasc. Pharmacol., 56, 329-335.
87. Decker, M., Arand, M., and Cronin, A. (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch. Toxicol., 83, 297-318.
88. Carr, P.D. and Ollis, D.L. (2009) Alpha/ beta hydrolase fold:an update. Protein Pept. Lett., 16, 1137-1148.
89. Haeggström, J.Z., Tholander, F., and Wetterholm, A. (2007) Structure and catalytic mechanisms of leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat., 83, 198-202.
90. Tholander, F., Muroya, A., Roques, B.P., Fournié-Zaluski, M.C., Thunnissen, M.M., and Haeggström, J.Z. (2008) Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase:implications for M1 aminopeptidases and inhibitor design. Chem. Biol., 15, 920-929.
91. de Medina, P., Paillasse, M.R., Segala, G., Poirot, M., and Silvente-Poirot, S. (2010) Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc. Natl. Acad. Sci. USA, 107, 13520-13525.
92. Camps, J., Marsillach, J., and Joven, J. (2009) The paraoxonases:role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci., 46, 83-106.
93. Khersonsky, O. and Tawfik, D.S. (2006) The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem., 281, 7649-7656.
94. Draganov, D.I. (2010) Lactonases with organophosphatase activity:structural and evolutionary perspectives. Chem. Biol. Interact., 187, 370-372.
95. Gupta, N., Gill, K., and Singh, S. (2009) Paraoxonases:structure, gene polymorphism and role in coronary artery disease. Indian J. Med. Res., 130, 361-368.
96. Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R.B., McCarthy, A., Toker, L., Silman, I., Sussman, J.L., and Tawfik, D.S. (2004) Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol., 11, 412-419.
97. Rozenberg, O., Rosenblat, M., Coleman, R., Shih, D.M., and Aviram, M. (2003) Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress:studies in PON1-knockout mice. Free Radic. Biol. Med., 34, 774-784.
98. Shih, D.M., Xia, Y.R., Wang, X.P., Wang, S.S., Bourquard, N., Fogelman, A.M., Lusis, A.J., and Reddy, S.T. (2007) Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ. Res., 100, 1200-1207.
99. Tougou, K., Nakamura, A., Watanabe, S., Okuyama, Y., and Morino, A. (1998) Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab. Dispos., 26, 355-359.
100. Mackenzie Ross, S.J., Brewin, C.R., Curran, H.V., Furlong, C.E., Abraham-Smith, K.M., and Harrison, V. (2010) Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides. Neurotoxicol. Teratol., 32, 452-459.
101. Shih, D.M., Gu, L., Xia, Y.R., Navab, M., Li, W.F., Hama, S., Castellani, L.W., Furlong, C.E., Costa, L.G., Fogelman, A.M., and Lusis, A.J. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 394, 284-287.
102. Jansen, K.L., Cole, T.B., Park, S.S., Furlong, C.E., and Costa, L.G. (2009) Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol. Appl. Pharmacol., 236, 142-153.
103. Primo-Parmo, S.L., Sorenson, R.C., Teiber, J., and La Du, B.N. (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 33, 498-507.
104. Draganov, D.I. and La Du, B.N. (2004) Pharmacogenetics of paraoxonases:a brief review. Naunyn Schmiedebergs Arch. Pharmacol., 369, 78-88.
105. bin Ali, A., Zhang, Q., Lim, Y.K., Fang, D., Retnam, L., and Lim, S.K. (2003) Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic. Biol. Med., 34, 824-829.
106. Precourt, L.P., Seidman, E., Delvin, E., Amre, D., Deslandres, C., Dominguez, M., Sinnett, D., and Levy, E. (2009) Comparative expression analysis reveals differences in the regulation of intestinal paraoxonase family members. Int. J. Biochem. Cell Biol., 41, 1628-1637.
107. Gouédard, C., Barouki, R., and Morel, Y. (2004) Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell. Biol., 24, 5209-5222.
108. Shiner, M., Fuhrman, B., and Aviram, M. (2007) Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic antioxidants via PPAR gamma and AP-1 pathway activation. Atherosclerosis, 195, 313-321.
109. Arii, K., Suehiro, T., Ikeda, Y., Kumon, Y., Inoue, M., Inada, S., Takata, H., Ishibashi, A., Hashimoto, K., and Terada, Y. (2010) Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells. Metabolism, 59, 1287-1293.
110. Gouédard, C., Koum-Besson, N., Barouki, R., and Morel, Y. (2003) Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol., 63, 945-956.
111. Fuhrman, B., Gantman, A., and Aviram, M. (2010) Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis, 211, 61-68.
112. Khersonsky, O. and Tawfik, D.S. (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry, 44, 6371-6382.
113. Jakubowski, H. (2010) The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv. Exp. Med. Biol., 660, 113-127.
114. Teiber, J.F., Draganov, D.I., and La Du, B.N. (2003) Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol., 66, 887-896.
115. Sinan, S., Kockar, F., Gencer, N., Yildirim, H., and Arslan, O. (2006) Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol. Pharm. Bull., 29, 1559-1563.
116. Işgör, M.M. and Beydemir, S. (2010) Some cardiovascular therapeutics inhibit paraoxonase 1 (PON1) from human serum. Eur. J. Pharmacol., 645, 135-142.
117. Park, C.H., Nguyen, S.D., Kim, M.R., Jeong, T.S., and Sok, D.E. (2006) Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound. Lipids, 41, 371-380.
118. Nguyen, S.D., Hung, N.D., Cheon-Ho, P., Ree, K.M., and Dai-Eun, S. (2009) Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim. Biophys. Acta, 1790, 155-160.
119. Isik, S., Kockar, F., Aydin, M., Arslan, O., Guler, O.O., Innocenti, A., Scozzafava, A., and Supuran, C.T. (2009) Carbonic anhydrase inhibitors:inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. Bioorg. Med. Chem., 17, 1158-1163.
120. Darreh-Shori, T. and Soininen, H. (2010) Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease:a review of recent clinical studies. Curr. Alzheimer Res., 7, 67-73.
121. Moriarty, L.M., Lally, M.N., Carolan, C.G., Jones, M., Clancy, J.M., and Gilmer, J.F. (2008) Discovery of a "true" aspirin prodrug. J. Med. Chem., 51, 7991-7999.
122. Hamon, F., Renoux, B., Chadéneau, C., Muller, J.M., and Papot, S. (2010) Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma. Eur.J. Med. Chem., 45, 1678-1682.
123. Lalanne, M., Khoury, H., Deroussent, A., Bosquet, N., Benech, H., Clayette, P., Couvreur, P., Vassal, G., Paci, A., and Andrieux, K. (2009) Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry. Int. J. Pharm., 379, 235-243.
124. Cattaneo, A. (2010) Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr. Opin. Mol. Ther., 12, 94-106.
125. Lai, L., Xu, Z., Zhou, J., Lee, K.D., and Amidon, G.L. (2008) Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J. Biol. Chem., 283, 9318-9327.